Details

Autor(en) / Beteiligte

• Hou, Fan Fan
• Zhang, Xun
• Zhang, Wei Ru
• Zhang, Guo Hua
• Xie, Di
• Chen, Ping Yan
• Jiang, Jian Ping
• Liang, Min
• Wang, Guo Bao
• Liu, Zheng Rong
• Geng, Ren Wen

Titel

Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency

Ist Teil von

• The New England journal of medicine, 2006-01, Vol.354 (2), p.131-140

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2006

Quelle

MEDLINE

Beschreibungen/Notizen

• Angiotensin-converting–enzyme (ACE) inhibitors provide renal protection in patients with mild-to-moderate renal insufficiency, slowing progression. However, the efficacy and safety of this class of medications in patients with advanced renal insufficiency are less clear. The results of this randomized, double-blind study indicate that benazepril, an ACE inhibitor, confers substantial renal benefits in patients without diabetes who have advanced renal insufficiency. The results of this randomized, double-blind study indicate that benazepril, an ACE inhibitor, confers substantial renal benefits in patients without diabetes who have advanced renal insufficiency. Angiotensin-converting–enzyme (ACE) inhibitors slow the progression of chronic kidney disease in the presence or absence of diabetes, particularly in patients with mild-to-moderate renal insufficiency, as reflected by a serum creatinine level of 1.5 to 3.0 mg per deciliter (133 to 265 μmol per liter). 1 – 3 Data, however, have been limited to patients with serum creatinine levels of 3.0 mg per deciliter or less. Many physicians are reluctant to use ACE inhibitors in patients with advanced renal insufficiency because of concern that serum creatinine or potassium levels will rise. 4 , 5 Many infer that the unique benefits of these drugs in patients . . .